Icon acquires Mapi Group, ups financial guidances

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Kritchanut)
(Image: iStock/Kritchanut)
Icon plc is expanding its commercialization offerings through its has acquisition of Mapi Group, a global research company.

The Mapi Group was founded in 1974 and provides real-world evidence, strategic regulatory services, pharmacovigilance, market access, and language services to support commercialization.

Through the acquisition, Icon will also have access to Mapi Research Trust, a non-profit that provides outcomes research globally.

Per the company’s website, the Trust features more than 4,000 clinical outcomes assessments (COA), more than 40,000 COA translations, and a research library with more than 29,000 COAs.

Dr. Steve Cutler, Icon CEO commented in the press release: “Our customers will also benefit from ICON’s access to the industry’s broadest set of COA tools and instruments as well as new and enhanced real world data set​s.”

Following the acquisition, Icon has increased its earnings and revenue guidances.

According to the company’s earnings results, also published today, the earnings guidance has been increased from a range of $5.06 - $5.26bn to $5.18 - $5.38bn. Revenue guidance increased from a range of $1.70 - $1.75bn to $1.74 - $1.77bn.

Icon reported gross business wins of $649m in the second quarter and cancelations of $86m, which resulted in net business wins of $563 million and a net book to bill of 1.31.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars